Name | Number of supported studies | Average coverage | |
---|---|---|---|
platelet | 4 studies | 24% ± 8% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 18% ± 3% | |
natural killer cell | 4 studies | 16% ± 1% | |
classical monocyte | 3 studies | 20% ± 4% | |
non-classical monocyte | 3 studies | 23% ± 4% | |
dendritic cell | 3 studies | 22% ± 4% |
Insufficient scRNA-seq data for expression of IKBKG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 407.58 | 1445 / 1445 | 100% | 4.39 | 183 / 183 |
lung | 100% | 521.71 | 578 / 578 | 99% | 6.69 | 1146 / 1155 |
skin | 100% | 467.20 | 1809 / 1809 | 99% | 6.99 | 468 / 472 |
stomach | 100% | 331.14 | 359 / 359 | 99% | 4.37 | 282 / 286 |
intestine | 100% | 401.09 | 966 / 966 | 98% | 4.53 | 519 / 527 |
breast | 100% | 432.02 | 459 / 459 | 98% | 5.11 | 1099 / 1118 |
bladder | 100% | 435.33 | 21 / 21 | 98% | 5.58 | 494 / 504 |
prostate | 100% | 357.37 | 245 / 245 | 97% | 4.37 | 489 / 502 |
thymus | 100% | 448.48 | 652 / 653 | 98% | 4.85 | 590 / 605 |
uterus | 100% | 428.38 | 170 / 170 | 97% | 6.93 | 445 / 459 |
kidney | 100% | 293.99 | 89 / 89 | 97% | 4.13 | 872 / 901 |
liver | 100% | 556.07 | 226 / 226 | 96% | 8.45 | 391 / 406 |
ovary | 100% | 324.88 | 180 / 180 | 96% | 3.33 | 414 / 430 |
brain | 97% | 242.50 | 2552 / 2642 | 100% | 5.66 | 702 / 705 |
pancreas | 97% | 185.24 | 319 / 328 | 98% | 5.24 | 175 / 178 |
adrenal gland | 100% | 530.94 | 258 / 258 | 93% | 4.58 | 215 / 230 |
adipose | 100% | 449.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 423.94 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 603.28 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 7.79 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.15 | 1 / 1 |
peripheral blood | 100% | 687.95 | 928 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 241.20 | 798 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 4.28 | 79 / 80 |
heart | 97% | 234.26 | 834 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 9.21 | 28 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050862 | Biological process | positive regulation of T cell receptor signaling pathway |
GO_0006954 | Biological process | inflammatory response |
GO_0045087 | Biological process | innate immune response |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0009615 | Biological process | response to virus |
GO_0006974 | Biological process | DNA damage response |
GO_0043276 | Biological process | anoikis |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0006955 | Biological process | immune response |
GO_2000060 | Biological process | positive regulation of ubiquitin-dependent protein catabolic process |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0042742 | Biological process | defense response to bacterium |
GO_0006915 | Biological process | apoptotic process |
GO_0051650 | Biological process | establishment of vesicle localization |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0000922 | Cellular component | spindle pole |
GO_0072686 | Cellular component | mitotic spindle |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008385 | Cellular component | IkappaB kinase complex |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_1990459 | Molecular function | transferrin receptor binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_1990450 | Molecular function | linear polyubiquitin binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0035591 | Molecular function | signaling adaptor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IKBKG |
Protein name | NF-kappa-B essential modulator (NEMO) (FIP-3) (IkB kinase-associated protein 1) (IKKAP1) (Inhibitor of nuclear factor kappa-B kinase subunit gamma) (I-kappa-B kinase subunit gamma) (IKK-gamma) (IKKG) (IkB kinase subunit gamma) (NF-kappa-B essential modifier) Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma, isoform CRA_b (Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma) NF-kappa-B essential modulator (IkB kinase-associated protein 1) (Inhibitor of nuclear factor kappa-B kinase subunit gamma) (NF-kappa-B essential modifier) NF-kappa-B essential modulator |
Synonyms | FIP3 NEMO hCG_2003089 |
Description | FUNCTION: Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor . Its binding to scaffolding polyubiquitin plays a key role in IKK activation by multiple signaling receptor pathways . Can recognize and bind both 'Lys-63'-linked and linear polyubiquitin upon cell stimulation, with a much higher affinity for linear polyubiquitin . Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3 . Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination . .; FUNCTION: (Microbial infection) Also considered to be a mediator for HTLV-1 Tax oncoprotein activation of NF-kappa-B. . |
Accessions | C9JN51 ENST00000689906.1 A0A087WUW6 ENST00000692948.1 ENST00000445622 A0A8I5KQX5 ENST00000422680 ENST00000594239.6 [Q9Y6K9-1] ENST00000440286 ENST00000619941.4 A0A087X1K7 C9JCG6 A0A087WWQ9 ENST00000445622.6 [Q9Y6K9-1] ENST00000615874.4 ENST00000611176.4 [Q9Y6K9-3] ENST00000612051.1 ENST00000618670.4 [Q9Y6K9-2] A0A087X1B1 ENST00000492469.3 Q9Y6K9 C9JH59 ENST00000686774.1 ENST00000440286.6 [Q9Y6K9-1] A0A8I5KQX1 ENST00000422680.6 [Q9Y6K9-1] A0A8I5KRU9 A0A087X0G7 ENST00000686378.1 A0A8I5KYQ7 ENST00000615186.5 C9J2V2 ENST00000617207.4 ENST00000611071.4 [Q9Y6K9-1] D3DWY0 ENST00000413620.6 |